The stock of Portola Pharmaceuticals Inc (NASDAQ:PTLA) is a huge mover today! About 1.11M shares traded hands or 20.03% up from the average. Portola Pharmaceuticals Inc (NASDAQ:PTLA) has declined 25.59% since March 3, 2016 and is downtrending. It has underperformed by 33.94% the S&P500.
The move comes after 9 months negative chart setup for the $1.23B company. It was reported on Oct, 6 by Barchart.com. We have $20.21 PT which if reached, will make NASDAQ:PTLA worth $73.80M less.
Analysts await Portola Pharmaceuticals Inc (NASDAQ:PTLA) to report earnings on November, 14. They expect $-1.11 earnings per share, down 5.71% or $0.06 from last year’s $-1.05 per share. After $-1.02 actual earnings per share reported by Portola Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 8.82% negative EPS growth.
Portola Pharmaceuticals Inc (NASDAQ:PTLA) Ratings Coverage
Out of 4 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 1 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 25% are positive. Portola Pharmaceuticals has been the topic of 11 analyst reports since August 5, 2015 according to StockzIntelligence Inc. Credit Suisse maintained the stock with “Neutral” rating in Friday, August 19 report. The firm earned “Buy” rating on Friday, May 27 by Citigroup. The stock has “Buy” rating given by Cowen & Co on Wednesday, August 5. The rating was downgraded by Citigroup to “Neutral” on Friday, August 19. The stock has “Overweight” rating given by Morgan Stanley on Friday, August 19. The rating was maintained by Citigroup with “Buy” on Wednesday, August 10. The firm earned “Buy” rating on Friday, December 18 by Goldman Sachs. The stock has “Outperform” rating given by Credit Suisse on Monday, March 28. Goldman Sachs downgraded Portola Pharmaceuticals Inc (NASDAQ:PTLA) on Monday, March 28 to “Neutral” rating. Credit Suisse downgraded the stock to “Neutral” rating in Tuesday, May 31 report.
According to Zacks Investment Research, “Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California.”
Insitutional Activity: The institutional sentiment increased to 1.09 in 2016 Q2. Its up 0.03, from 1.06 in 2016Q1. The ratio is positive, as 26 funds sold all Portola Pharmaceuticals Inc shares owned while 43 reduced positions. 16 funds bought stakes while 59 increased positions. They now own 51.75 million shares or 1.93% less from 52.77 million shares in 2016Q1.
Pictet Asset Mgmt Ltd last reported 0.07% of its portfolio in the stock. Profund Advisors Limited Company, a Maryland-based fund reported 31,880 shares. Goldman Sachs Gru has 0% invested in the company for 127,306 shares. Focused Wealth Management Inc has invested 0% of its portfolio in Portola Pharmaceuticals Inc (NASDAQ:PTLA). Marshall Wace Limited Liability Partnership holds 0.01% or 33,685 shares in its portfolio. The Florida-based Harvey Cap has invested 2.44% in Portola Pharmaceuticals Inc (NASDAQ:PTLA). Qs Invsts Limited Liability has 11 shares for 0% of their US portfolio. Los Angeles Cap Mgmt & Equity Research has 0% invested in the company for 9,745 shares. Fisher Asset Mngmt reported 82,737 shares or 0% of all its holdings. Blackrock Institutional Co Na last reported 1.35M shares in the company. New York State Common Retirement Fund holds 0% of its portfolio in Portola Pharmaceuticals Inc (NASDAQ:PTLA) for 53,888 shares. Moreover, Lazard Asset Lc has 0.02% invested in Portola Pharmaceuticals Inc (NASDAQ:PTLA) for 291,408 shares. Checchi Advisers holds 0% of its portfolio in Portola Pharmaceuticals Inc (NASDAQ:PTLA) for 373 shares. Fmr Ltd Limited Liability Company accumulated 0.02% or 6.32M shares. Blackrock Fund Advsr holds 0.01% or 1.95M shares in its portfolio.
Insider Transactions: Since May 2, 2016, the stock had 0 buys, and 1 sale for $135,406 net activity. Lis William had sold 5,675 shares worth $135,406 on Monday, May 2.
More notable recent Portola Pharmaceuticals Inc (NASDAQ:PTLA) news were published by: Fool.com which released: “Why Portola Pharmaceuticals Inc Is Plunging Today” on August 18, 2016, also Fool.com with their article: “Why Portola Pharmaceuticals, Inc. Increased 11.6% in April” published on May 11, 2016, Fool.com published: “Why Portola Pharmaceuticals Inc’s Stock Is Bleeding Red Today” on March 24, 2016. More interesting news about Portola Pharmaceuticals Inc (NASDAQ:PTLA) were released by: Fool.com and their article: “Portola Pharmaceuticals: Does New Data Get It Back on Track?” published on May 28, 2016 as well as Fool.com‘s news article titled: “Why Portola Pharmaceuticals Shares Jumped 82% in 2015” with publication date: January 07, 2016.
PTLA Company Profile
Portola Pharmaceuticals, Inc., incorporated on September 2, 2003, is a biopharmaceutical company. The Firm is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. The Company’s third product candidate is Cerdulatinib. The Company’s Syk is a mediator of immune response in various types of immune cells. The Firm has a program of highly selective Syk inhibitors, one of which is partnered with Ora Inc.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.